```html

Zaire ebolavirus Disease (Ebola Virus Disease)

Overview

Zaire ebolavirus disease, commonly referred to as Ebola Virus Disease (EVD), is a severe, often fatal illness caused by infection with the Zaire species of Ebolavirus. It belongs to the Filoviridae family, which also includes Marburg virus. The disease was first recognized in 1976 during simultaneous outbreaks in the Democratic Republic of Congo (then Zaire) and Sudan.

The virus spreads primarily through direct contact with the blood, secretions, organs, or other bodily fluids of infected people or animals. Person‑to‑person transmission is most common within households, healthcare settings, and during burial rituals.

Who it affects

• People living in or traveling to regions of Central and West Africa where the virus circulates (e.g., Democratic Republic of Congo, Uganda, Guinea, Sierra Leone, Liberia, and recently the Republic of the Congo).
• Healthcare workers and laboratory personnel without adequate personal protective equipment (PPE).
• Family members and traditional burial attendants who handle the deceased.
• People who handle or consume bush‑meat (especially fruit bats, non‑human primates) from endemic areas.

Prevalence

Since 1976, >35 documented outbreaks have occurred, accounting for roughly 30,000 suspected cases and 13,000 laboratory‑confirmed infections. The largest outbreak (2014‑2016) in West Africa resulted in 28,616 cases and 11,310 deaths, a case‑fatality rate (CFR) of ~39 % (World Health Organization, 2024). More recent outbreaks in the Democratic Republic of Congo (2018‑2020, 2020‑2022) have shown CFRs ranging from 30 % to 70 % depending on early detection and supportive care availability.

Symptoms

Symptoms typically appear 2–21 days (median ≈ 8‑10 days) after exposure. Early signs are nonspecific and resemble other viral infections, making early diagnosis challenging.

• Fever – ≥38 °C (100.4 °F). Often the first symptom.
• Severe headache – Persistent, may be throbbing.
• Muscle and joint pain – “Body aches” that can be intense.
• Fatigue and weakness – Progressive exhaustion.
• Sore throat – May progress to dysphagia.
• Gastrointestinal symptoms – Nausea, vomiting, diarrhea, and abdominal pain. These can lead to rapid fluid loss.
• Rash – Maculopapular rash often appears on the trunk.
• Conjunctival hemorrhage – Red eyes with bleeding under the conjunctiva.
• Hemorrhagic signs – Petechiae, bruising, bleeding from gums, nose, or gastrointestinal tract; can be subtle early on but become prominent in severe cases.
• Neurologic changes – Confusion, agitation, seizures, or coma in later stages.

The disease progresses in three stages: (1) incubation, (2) acute phase with systemic symptoms, and (3) convalescent phase for survivors who may experience lingering fatigue, joint pain, or eye problems (e.g., uveitis).

Causes and Risk Factors

Cause

Zaire ebolavirus is an RNA virus transmitted to humans through:

• Direct contact with infected wildlife (fruit bats are the probable natural reservoir; non‑human primates and duikers act as amplifying hosts).
• Handling or consumption of raw or undercooked bush‑meat.
• Exposure to contaminated surfaces or medical equipment.

Risk Factors

• Geographic exposure – Living in or traveling to endemic regions.
• Occupational exposure – Healthcare, laboratory, or field work without proper PPE.
• Cultural practices – Traditional burial rituals that involve washing or touching the body.
• Close household contact – Caring for a sick family member without barrier protection.
• Limited access to clean water and sanitation – Increases likelihood of skin breaches and secondary infections.

Diagnosis

Because early symptoms overlap with malaria, typhoid, and other viral infections, a high index of suspicion is essential, especially during known outbreaks.

Clinical assessment

• Detailed exposure history (travel, contact with ill persons/animals, participation in burial rites).
• Physical examination focusing on bleeding manifestations and organ involvement.

Laboratory tests

1. RT‑PCR (reverse transcription polymerase chain reaction) – Gold‑standard for detecting viral RNA in blood, urine, or saliva. Results are available within hours in equipped labs.
2. Antigen‑capture ELISA – Detects viral proteins; useful when PCR is unavailable.
3. Serology (IgM/IgG ELISA) – Indicates recent or past infection; not useful for acute diagnosis.
4. Virus isolation – Performed only in high‑containment (BSL‑4) facilities.
5. Complete blood count – Often shows leukopenia, thrombocytopenia, and elevated liver enzymes.

All specimens must be handled with strict infection‑control protocols (WHO, 2023). In many endemic areas, rapid point‑of‑care RT‑PCR platforms have been deployed to shorten time to diagnosis.

Treatment Options

There is no single “cure,” but several therapies have demonstrated benefit, especially when started early.

Antiviral medications

• Inmazeb (atoltivimab, maftivimab, odesivimab‑ebgn) – A triple‑monoclonal antibody cocktail approved by the FDA (2020) and WHO for Zaire ebolavirus. Given as a single IV infusion within 7 days of symptom onset.
• Ebanga (ansuvimab‑by‑kmn) – Single‑dose monoclonal antibody approved in the EU and US (2020). Shows reduced mortality when administered early.
• Remdesivir – Broad‑spectrum antiviral; limited data suggest modest benefit, currently used under compassionate‑use protocols.

Supportive care (the cornerstone of therapy)

• Intravenous fluid replacement to correct dehydration and electrolyte imbalances.
• Blood product transfusions (packed RBCs, platelets, plasma) for hemorrhage and coagulopathy.
• Broad‑spectrum antibiotics to treat secondary bacterial infections.
• Oxygen therapy, and mechanical ventilation for respiratory failure.
• Renal replacement therapy (dialysis) if acute kidney injury develops.

Procedures & adjuncts

• Strict isolation in a dedicated Ebola Treatment Unit (ETU) with negative‑pressure rooms.
• Use of PPE (fluid‑impermeable gowns, double gloves, face shields, N95/FFP2 respirators).
• Psychological support for patients and families.

Lifestyle / home‑based measures (post‑recovery)

• Gradual return to activity; avoid heavy exertion for 4–6 weeks.
• Regular ophthalmologic exams if eye involvement was present.
• Vaccination with the recombinant vesicular stomatitis virus–Zaire Ebola vaccine (rVSV‑ZEBOV) for survivors and close contacts, where available.

Living with Zaire ebolavirus Disease

Survivors often face long‑term sequelae, termed “post‑Ebola syndrome.” Managing these issues improves quality of life.

Physical health

• Hydration and nutrition – Small, frequent meals rich in protein and vitamins support tissue repair.
• Joint and muscle pain – NSAIDs (e.g., ibuprofen) as tolerated; physiotherapy can restore range of motion.
• Eye problems – Prompt referral to an ophthalmologist for uveitis; corticosteroid eye drops may be needed.
• Neurologic symptoms – Cognitive rehabilitation and seizure prophylaxis if indicated.

Psychological well‑being

• Stigma is common; community education reduces discrimination.
• Access counseling, peer‑support groups, and, when needed, antidepressant therapy.

Follow‑up care

Schedule visits with an infectious‑disease specialist at 2 weeks, 1 month, 3 months, and 6 months post‑discharge. Laboratory monitoring (CBC, LFTs, renal function) should be repeated at each visit.

Prevention

Vaccination

The rVSV‑ZEBOV vaccine (Ervebo) provides ~97 % efficacy when administered 10 days before exposure (PREVAIL trial, NEJM 2019). It is recommended for:

• Healthcare workers in endemic regions.
• Laboratory staff handling Ebola specimens.
• Individuals at high risk (e.g., bush‑meat hunters, contacts of a confirmed case).

Infection‑control practices

• Full PPE for any contact with suspected or confirmed patients.
• Safe burial protocols – use of impermeable body bags, trained burial teams, and disinfection of surfaces.
• Hand hygiene with alcohol‑based hand rubs or soap and water for ≥20 seconds.
• Environmental cleaning with 0.5 % chlorine solution or EPA‑approved disinfectants.

Public‑health measures

• Rapid case identification and contact tracing.
• Community education about avoiding contact with bush‑meat and dead wildlife.
• Strengthening laboratory capacity for quick RT‑PCR testing.

Complications

If untreated or managed inadequately, Zaire ebolavirus can cause life‑threatening complications:

• Severe hemorrhage – Gastrointestinal, mucosal, or intracranial bleeding.
• Multi‑organ failure – Liver, kidneys, heart, and lungs may all fail.
• Septic shock – Due to bacterial translocation from a compromised gut.
• Neurologic damage – Encephalitis, seizures, lasting cognitive deficits.
• Vision loss – Uveitis or retinal scarring.
• Persistent viral reservoirs – Ebola RNA has been detected in semen up to 18 months; sexual transmission has been documented.

When to Seek Emergency Care

References

1. World Health Organization. Ebola Virus Disease. Updated 2024.
2. Mayo Clinic. Ebola Virus Disease – Symptoms & Causes. 2023.
3. CDC. Ebola (Ebola Virus Disease). 2024.
4. NIH National Institute of Allergy and Infectious Diseases. Ebola Virus. 2023.
5. Henao‑Restrepo, A. et al. “Efficacy and safety of two monoclonal antibody treatments for Zaire Ebola virus disease.” New England Journal of Medicine. 2019;381:1445‑1452.
6. WHO. Clinical Management of Patients with Viral Haemorrhagic Fever. 2023.
7. Cleveland Clinic. Ebola Virus Disease. 2022.

```